Convenient and discreet, ODTs are popular
with patients and physicians. The CIMA ODT
portfolio includes a variety of options for dose,
release profiles, colors, flavors, disintegration
time and packaging.
Drugs delivered across oral mucosal
membranes bypass the gastrointestinal tract
thus reducing the first pass effect of the liver.
Transmucosal delivery can also improve the rate
and extent of absorption of some drugs. CIMA
offers two unique technologies in this category.
Oral granules and powders can accommodate
higher doses than solid forms. Single dose
sachets make it easy for patients to carry;
taste-masking makes it easy to take.
Many potential drugs demonstrate therapeutic
activity but never make it through product
development. Improved solubilization can
rescue drugs with poor water solubility and turn
them into commercially viable products.
An unpleasant taste is a big barrier. To
overcome it, partner with an expert in taste-
masking. CIMA understands the complex
relationship between a drug's physicochemical
properties and its taste.
Without protection against tampering and
unintended dose-dumping, extended release
drugs may pose risks to patients. CIMA has
engineered a solution to help guard against
CIMA employs proven encapsulation
techniques to deliver customized release
CIMA drug delivery technologies help move molecules out of the lab and
into medicine cabinets. CIMA has commercialized more than 20 products sold in countries around the world.
Pharmaceutical and biotech companies partner with CIMA for its drug delivery technologies and proven commercialization success.
Leading pharmaceutical companies trust CIMA delivery technologies to commercialize new drugs and extend the life cycle of established products.